|January 2007 · Vol. 19, No. 01
HPV & CERVICAL SCREENING 2007
CO-SPONSORED BY THE CERVICAL CANCER
EDUCATION AND PREVENTION INITIATIVE
The new HPV vaccine:
What the ObGyn needs to know
Who should be immunized? Who pays? Should women over 26 be vaccinated? Is cervical screening on its way out?
Section Editor and Moderator
Chair, 2006 Consensus Conference, American Society for Colposcopy and Cervical Pathology
What once seemed far in the future is now a reality: the human papillomavirus (HPV) vaccine. The quadrivalent vaccine (Gardasil) that prevents the development of lesions caused by HPV types 6, 11, 16, and 18 was approved last June by the US Food and Drug Administration (FDA) for clinical use in females 9 to 26 years old. Shortly after its approval, the Advisory Committee on Immunization Practices (ACIP) issued guidelines on who should be vaccinated.
In light of these developments, OBG Management invited Dr. Tom Wright to convene an expert panel to discuss the ACIP recommendations and ways of introducing the vaccine into practice.